Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Jan 01, 2005 (Vol. 25, No. 1)


  • Nice design
  • None
Consider the number of organisms on earth, the number of common genes among them, and the number of databases of sequence information for each. Needless to say, the set size of any of these categories is large. A search of DNA polymerase for Bacillus subtilis might turn up numerous identical DNA sequences among different databases. How does one cut through the noise and find desired protein sequence information? As you might imagine, there is no single answer to the question, but one very good approach to the problem is taken by PIR-NREF (a twisted acronym for PIR Non-Redundant Protein REFerence Databases), that groups identical sequences in the PIR-PSD, SwissProt, TrEMBL, RefSeq, GenPept, and PDB databases into individual records. Searches by species, by FASTA, BLAST, and other algorithms are supported, with results neatly and nonredundantly organized.
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good

*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »